Results 111 to 120 of about 34,959 (356)
Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy [PDF]
, 2014 Hepatitis C virus (HCV) infection represents an important public health problem worldwide. Reduction of HCV morbidity and mortality is a current challenge owned to several viral and host factors.
Carpio Pedroza, Juan Carlos +10 more
core +1 more source
Advanced Science, EarlyView.RNF213 is characterized as a dual‐functional antiviral effector. It directly mediates the degradation of the influenza A virus nucleoprotein (NP) while simultaneously activating the MDA5‐mediated innate immune signaling pathway. This coordinated response establishes a powerful host defense system against viral infection. ABSTRACT Influenza A virus (IAV)
Haoning Li +5 more
wiley +1 more source
Hepatitis C in Children—An Asia–Pacific Concise Perspective
PathogensSince the discovery of hepatitis C virus (HCV) in 1989, we now have curative treatment options with direct-acting antiviral therapies. By increasing the rate of treatment and reducing transmission, the eradication of HCV is potentially achievable ...
Lynette Goh, Winita Hardikar
doaj +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
Norovirus antiviral discovery: host-modulators and direct-acting antivirals
, 2018 Human norovirus is a leading cause of acute gastroenteritis (AGE) worldwide and is estimated to be responsible for over 200,000 deaths each year. Norovirus infections are estimated to cost $60 billion in societal costs globally each year. Yet despite the substantial health and economic burden of norovirus, there is no vaccine or norovirus-specific ...
openaire +2 more sources
Advanced Science, EarlyView.By integrating data from in vitro, ex vivo, and in vivo models, our research identifies the MARV glycoprotein as a remarkable hemorrhagic factor, filling a major gap in this important field. It also provides practical experimental tools for the basic research on viral pathogenesis and applied research aimed at antiviral intervention for hemorrhagic ...
Ting Yao +11 more
wiley +1 more source
Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
Journal of Virus Eradication, 2018 Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to ...
Andrew Hill +8 more
doaj +1 more source
Editorial Commentary: Does HIV Remain a Risk Factor for Achieving Sustained Virologic Response Under Direct Acting Antiviral-Based Modern Hepatitis C Virus Therapy? [PDF]
, 2014 Jürgen K. Rockstroh
openalex +1 more source
Advanced Science, EarlyView.An integrated approach combining mass spectrometry imaging, transcriptomics, and phylogenetic analysis facilitated the efficient identification of genes involved in gallotannin biosynthesis in Paeonia suffruticosa. As a result, a key UGT and several SCPL acyltransferases responsible for biosynthesizing pentagalloylglucose were successfully identified ...
Yushi Liu +4 more
wiley +1 more source
New Potential Therapies for Chronic Hepatitis B
The Korean Journal of Gastroenterology, 2019 A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective in inhibiting HBV ...
Sun Hong Yoo, Jung Hyun Kwon
doaj +1 more source